Arrowhead Research | ARWR - Net Income

Stock Price
27.58
Daily Change
-1.50 -5.16%
Monthly
60.26%
Yearly
26.75%
Q3 Forecast
28.84

Arrowhead Research reported $-175241000 in Net Income for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 1.38B
Cash and Equivalent USD 129.79M
Current Assets USD 946.92M
Current Liabilities USD 194.53M
Debt USD 388.24M
EBIT USD -165.55M
EBITDA USD -159.33M
Employees 609
EPS Earnings Per Share USD -1.26
Equity Capital and Reserves USD 522.31M
Gross Profit on Sales USD 27.77M
Interest Expense on Debt USD 24.38M
Interest Income USD 9.62M
Loan Capital USD 200.33M
Market Capitalization USD 3.51B
Net Income USD -175.24M
Operating Expenses USD 193.32M
Operating Profit USD -165.55M
Ordinary Share Capital USD 138.14M
PE Price to Earnings USD 436.79
Pre-Tax Profit USD -179.09M
Sales Revenues USD 27.77M
Selling and Administration Expenses USD 30.95M
Stock USD -173.09M
Trade Creditors USD 33.05M
Trade Debtors USD 9.7M

Net Income Change Date
Agios Pharmaceuticals USD -112020000 22.73M Jun/2025
Alnylam Pharmaceuticals USD -66277000 8.8M Jun/2025
Arrowhead Research USD -175241000 545.69M Jun/2025
Incyte USD 405M 246.8M Jun/2025
Ionis Pharmaceuticals USD 123.55M 270.49M Jun/2025
Ligand Pharmaceuticals USD 4.85M 47.3M Jun/2025
Merck USD 4.43B 652M Jun/2025
Moderna USD -825000000 146M Jun/2025
Novartis USD 4.02B 418M Jun/2025
Sarepta Therapeutics USD 196.89M 644.4M Jun/2025
TG Therapeutics USD 28.19M 23.13M Jun/2025
Ultragenyx Pharmaceutical USD -114951000 36.13M Jun/2025
Vertex Pharmaceuticals USD 1.03B 386.6M Jun/2025
Xencor USD -30825000 17.59M Jun/2025